NASHVILLE, Tenn. / May 23, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.
William Blair 43rd Annual Growth Stock Conference
Chief Executive Officer Mark J. Foley is scheduled to participate in a fireside chat on Tuesday, June 6, 2023, at 4:00 P.M. CDT, in Chicago, Illinois.
Goldman Sachs 44th Annual Global Healthcare Conference
Chief Executive Officer Mark J. Foley and President Dustin S. Sjuts are scheduled to participate in a fireside chat on Monday, June 12, 2023, at 8:40 A.M. PDT, in Dana Point, California.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
| Last Trade: | US$2.71 |
| Daily Change: | 0.04 1.50 |
| Daily Volume: | 1,515,137 |
| Market Cap: | US$283.060M |
May 09, 2024 April 12, 2024 February 28, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
